Know Cancer

or
forgot password

Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence


N/A
18 Years
N/A
Open (Enrolling)
Both
Glioblastoma

Thank you

Trial Information

Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence


BACKGROUND

- Preliminary data generated from our pilot protocol 02-C-0064 suggests that the urinary
VEGF and MMP level at the one month follow-up time point compared to the last
on-treatment time point collection may be predictive of tumor recurrence at one year
(l).

- Note that this preliminary study included patients with all histologies.

- In an on ongoing effort to validate our results with a larger more homogeneous patient
cohort we propose to prospectively study patients undergoing radiotherapy for GBM.

OBJECTIVES

-We will determine the whether VEGF and MMP level measurements aide in predicting tumor
recurrence at 1 year.

ELIGIBILITY

-Patients seen in the radiation oncology clinic will be asked to provide samples of blood
and urine before, during and after their radiation treatment.

DESIGN

- This protocol-provides a means of acquiring blood and urine samples from patients
receiving radiation therapy for Glioblastoma multiforme (GBM).

- Patients will be stratified according to their Radiation Therapy Oncology Group (RTOG)
recursive partitioning prognostic subgroups, which includes patient age, KPS, extent of
resection and neurological function.

Inclusion Criteria


- INCLUSION CRITERIA:

Age greater than or equal to 18 years

Histologically confirmed supratentorial Glioblastoma multiforme

Karnofsky performance greater than 60

Patient must be a candidate for radiotherapy

EXCLUSION CRITERIA:

Inability to provide informed consent

Patients who have had prior radiotherapy to the brain

Patients with other cancers excluding nonmelanomatous skin cancers or carcinoma in situ

Gliadel wafer placement at the time of surgery

Type of Study:

Observational

Study Design:

N/A

Principal Investigator

Kevin A Camphausen, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)

Authority:

United States: Federal Government

Study ID:

040200

NCT ID:

NCT00083512

Start Date:

May 2004

Completion Date:

Related Keywords:

  • Glioblastoma
  • Blood
  • Urine
  • GBM
  • Radiation
  • Glioblastoma Multiforme
  • Glioblastoma

Name

Location

National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland  20892